More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...

At Envision Summit 2026, the “Fast and Fundus” retina panel delivered rapid-fire case discussions grounded in practical ...

Eylea HD injected every 12 or 16 weeks controls neovascular age-related macular degeneration to a similar extent as Eylea ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...

Patients with treatment-naive neovascular age-related macular degeneration have positive outcomes with faricimab at 1 year, ...

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...

Central vision loss from Age-related Macular Degeneration can begin subtly, faces blur, words distort, yet side vision ...

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...

A two-member medical team appointed by the Pakistani government under directions of the Supreme Court has submitted a detailed report on the health of former Prime Minister Imran Khan. According to ...

RMIT researchers have combined natural compounds with nanotechnology to develop a groundbreaking approach to eye health.

Investors were looking for a greater difference between Ocular’s experimental medicine and a low-dose version of Eylea, ...